1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDigital Europe Programme: AI-based image screening in medical centres is sponsored by European Commission (Digital Europe Programme). This call, expected to open under the Digital Europe Programme's 2026 work programme, focuses on deploying and scaling Artificial Intelligence applications in healthcare, specifically for AI-based image screening in medical centers.
Get alerted about grants like this
Save a search for “European Commission (Digital Europe Programme)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Info Day on digital health topics under the DIGITAL Europe Programme - Apply AI: Piloting AI-based image screening in medical centres | Shaping Europe’s digital future Info Day on digital health topics under the DIGITAL Europe Programme - Apply AI: Piloting AI-based image screening in medical centres Publication 29 April 2026 Discover the policy and funding requirements, get your questions answered, and pitch your organisation’s idea for a chance to pilot AI-powered screening services across Europe.
This online session will provide information for applicants interested in the call for proposals DIGITAL-2026-AI-PILOTING-10-SCREENING - Apply AI: Piloting AI-based image screening in medical centres. Join the live stream .
You can also submit your questions about the call ahead of the session via Slido , using the passcode: AI2105 This topic aims to accelerate the adoption and deployment of cloud-based AI systems running European AI algorithms for medical image screening, with a focus on the early detection and diagnosis of cancer and cardiovascular diseases. Two projects will be funded under this call for proposals.
These projects will pilot the deployment of cloud-based AI systems to: Improve efficiency in detection and diagnostic workflows in the areas of cancer and/or cardiovascular diseases Support the prioritisation of critical cases Reduce pressure on radiology services Contribute to more equitable access to screening services, including in underserved regions This topic contributes to the Apply AI strategy .
In particular, the flagship initiative European AI-powered advanced screening centres , which will speed up the introduction of innovative AI solutions for disease prevention, early detection and diagnosis, and support Europe’s fight against cancer and cardiovascular diseases.
€9 M (€4,5 M per project) Number of projects expected Indicative duration of the action 1 October 2026, 17:00 CET (Brussels) Anca SCORTARIU (CNECT A6) Anca SCORTARIU (CNECT A6) Call topic presentation: Apply AI: Piloting AI-based image screening in medical centres and Questions & Answers (Q&A) Matthieu RUTHVEN & Vanessa MENDES (CNECT A6) Financial requirements and guidance, and Q&A Restricted calls guidance and Q&A Mateja POGACIC (CNECT R5) Stakeholder presentations Organisations potentially interested in the call can register to present their organisation/idea in a dedicated pitching session (maximum 3 minutes and up to 3 slides per participant).
If you are interested, please register using the form . Please note that there are a limited number of pitching slots and these will be allocated on a first-come, first-served basis. For information about how the European Commission processes your personal data, please read the Privacy Statement below.
If you have any questions regarding the call, please contact your National Contact Point for Digital Europe or ask a question through the Q&A functionality in the Funding and Tender Portal .
For additional information on the Digital Europe Programme, check: Digital Europe Programme (DIGITAL) Amendment of the Digital Europe Work Programme 2025-2027 National Contact Points for Digital Europe Frequently Asked Questions (FAQ) Watch the video below to check on you can obtain a Participant Identification Code. Privacy statement for Info Day Call 10 - Apply AI
Based on current listing details, eligibility includes: Likely open to public authorities, SMEs, research and academic institutions, associations, and other entities from EU Member States and Associated Countries ready to implement digital solutions. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.